AbbVie expands board with new director
- Board expanded to 13 directors
- Dr. John M. Carethers appointed as Class II director
- Dr. Carethers joins Public Policy and Sustainability Committee
ABBV
AbbVie Inc. SEC filings
Every EDGAR filing for AbbVie Inc. (ABBV), newest first, with AI summaries and stories.
- Ticker
- ABBV
- CIK
- 1551152
- Sector
- Biotech and pharma
- Latest filing
- 3d
Next: earnings expected ~Oct 30 ยท 10-Q expected ~Nov 4 (deadline Nov 9)
Insider activity
No open-market insider buys in the last 30 days.
Filings
Every filing, newest first. MAJOR and NOTABLE filings lead the app's feed; ROUTINE ones are kept here.
MAJOR8-KAbbVie Inc.ABBVLIVE ROUTINE8-KAbbVie Inc.ABBVLIVE AbbVie Inc. reports Q3 2026 results
- Acquired IPR&D and milestones expense of $216M in Q3 2026
- GAAP and non-GAAP EPS impacted by $0.11 each
- Full-year 2026 adjusted EPS guidance: $13.76 - $13.96
ROUTINE4AbbVie Inc.ABBVLIVE 2 insider filings
Edward J Rapp, insider filing for ABBV
Show all 2
- 4Insider filing for ABBV
- 4Insider filing for ABBV
Edward J Rapp
ROUTINE8-KAbbVie Inc.ABBVLIVE ROUTINE4AbbVie Inc.ABBVLIVE Nicholas Donoghoe, insider filing for ABBV
Nicholas Donoghoe, reporting
ROUTINE8-KAbbVie Inc.ABBVLIVE ROUTINE144AbbVie Inc.ABBVLIVE Nicholas Donoghoe, planned sale of ABBV shares
Nicholas Donoghoe, reporting
ROUTINE424B5AbbVie Inc.ABBVLIVE ROUTINE8-KAbbVie Inc.ABBVLIVE ROUTINEFWPAbbVie Inc.ABBVLIVE ROUTINE424B5AbbVie Inc.ABBVLIVE NOTABLE10-QAbbVie Inc.ABBVLIVE ROUTINE8-KAbbVie Inc.ABBVLIVE ROUTINE8-KAbbVie Inc.ABBVLIVE ROUTINE4AbbVie Inc.ABBVLIVE 2 insider filings
Edward J Rapp, insider filing for ABBV
Show all 2
- 4Insider filing for ABBV
- 4Insider filing for ABBV
Edward J Rapp, reporting
ROUTINE11-KAbbVie Inc.ABBVLIVE ROUTINE8-KAbbVie Inc.ABBVLIVE ROUTINESDAbbVie Inc.ABBVLIVE ROUTINE144AbbVie Inc.ABBVLIVE Robert J Alpern, planned sale of ABBV shares
Robert J Alpern, reporting
ROUTINE8-KAbbVie Inc.ABBVLIVE ROUTINE4AbbVie Inc.ABBVLIVE 11 insider filings
Thomas J Falk, insider filing for ABBV
Show all 11
- 4Insider filing for ABBV
- 4Insider filing for ABBV
- 4Insider filing for ABBV
- 4Insider filing for ABBV
- 4Insider filing for ABBV
- 4Insider filing for ABBV
- 4Insider filing for ABBV
- 4Insider filing for ABBV
- 4Insider filing for ABBV
- 4Insider filing for ABBV
- 4Insider filing for ABBV
Thomas J Falk, reporting
NOTABLE10-QAbbVie Inc.ABBVLIVE ROUTINESCHEDULE 13GAbbVie Inc.ABBVLIVE Ownership stake disclosure by VANGUARD CAPITAL MANAGEMENT LLC
VANGUARD CAPITAL MANAGEMENT LLC, filed by
ROUTINE8-KAbbVie Inc.ABBVLIVE ROUTINE8-KAbbVie Inc.ABBVLIVE ROUTINE4AbbVie Inc.ABBVLIVE 3 insider filings
Robert J Alpern, insider filing for ABBV
Show all 3
- 4Insider filing for ABBV
- 4Insider filing for ABBV
- 4Insider filing for ABBV
Robert J Alpern, reporting
ROUTINESCHEDULE 13G/AAbbVie Inc.ABBVLIVE Ownership stake disclosure by VANGUARD GROUP INC (amended)
VANGUARD GROUP INC, filed by
ROUTINEARSAbbVie Inc.ABBVLIVE ROUTINEDEFA14AAbbVie Inc.ABBVLIVE ROUTINEDEF 14AAbbVie Inc.ABBVLIVE ROUTINE4/AAbbVie Inc.ABBVLIVE David Ryan Purdue, insider filing for ABBV (amended)
David Ryan Purdue, reporting
ROUTINEPRE 14AAbbVie Inc.ABBVLIVE ROUTINE4AbbVie Inc.ABBVLIVE 2 insider filings
David Ryan Purdue, insider filing for ABBV
Show all 2
- 4Insider filing for ABBV
- 4Insider filing for ABBV
David Ryan Purdue, reporting
ROUTINE144AbbVie Inc.ABBVLIVE David Ryan Purdue, planned sale of ABBV shares
David Ryan Purdue, reporting
ROUTINE8-KAbbVie Inc.ABBVLIVE